A double blind, randomised, placebo controlled, parallel group study of Sativex when added to the existing treatment regimen, in the relief of post-herpetic neuralgia.
Phase of Trial: Phase III
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Cannabidiol (Primary)
- Indications Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors GW Pharmaceuticals
- 28 Jul 2017 Status changed from recruiting to discontinued.
- 14 Jun 2011 New trial record